Elekta AB (publ) - EKTAY Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $69.00
  • Forecasted Upside: 1,097.92 %
  • Number of Analysts: 4
  • Breakdown:
  • 3 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.76
▼ -0.16 (-2.70%)

This chart shows the closing price for EKTAY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Elekta AB (publ) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EKTAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EKTAY

Analyst Price Target is $69.00
▲ +1,097.92% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Elekta AB (publ) in the last 3 months. The average price target is $69.00, with a high forecast of $69.00 and a low forecast of $69.00. The average price target represents a 1,097.92% upside from the last price of $5.76.

This chart shows the closing price for EKTAY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Sell

The current consensus among 4 polled investment analysts is to sell stock in Elekta AB (publ). This rating has held steady since January 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 2 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 2 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 3 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 3 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/18/2022Morgan StanleyInitiated CoverageUnderweight
4/26/2022JPMorgan Chase & Co.Lower TargetUnderweight ➝ UnderweightSEK 79 ➝ SEK 69
2/25/2022JPMorgan Chase & Co.Lower TargetSEK 87 ➝ SEK 79
2/15/2022DanskeDowngradeBuy ➝ Hold
1/20/2022Jefferies Financial GroupInitiated CoverageUnderperform
8/27/2021JPMorgan Chase & Co.Reiterated RatingUnderweight
6/2/2021JPMorgan Chase & Co.Reiterated RatingUnderweight
4/27/2021JPMorgan Chase & Co.Reiterated RatingUnderweight
3/18/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
1/20/2021Berenberg BankReiterated RatingBuy
1/7/2021Northland SecuritiesInitiated CoverageOutperform
12/9/2020Morgan StanleyDowngradeEqual Weight ➝ Underweight
11/27/2020JPMorgan Chase & Co.Reiterated RatingNeutral
10/26/2020JPMorgan Chase & Co.Reiterated RatingNeutral
9/9/2020Morgan StanleyReiterated RatingEqual Weight
9/3/2020Berenberg BankReiterated RatingBuy
8/27/2020JPMorgan Chase & Co.Reiterated RatingNeutral
8/3/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
7/29/2020Morgan StanleyUpgradeUnderweight ➝ Equal Weight
6/1/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
5/7/2020UBS GroupDowngradeBuy ➝ Neutral
4/29/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
2/21/2020Pareto SecuritiesDowngradeBuy ➝ Hold
7/16/2019Jefferies Financial GroupUpgradeUnderperform ➝ Hold
11/28/2018UBS GroupUpgradeNeutral ➝ Buy
(Data available from 12/7/2017 forward)

News Sentiment Rating

1.81 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/11/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/7/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2022

Current Sentiment

  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.
Elekta AB (publ) logo
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
Read More

Today's Range

Now: $5.76
Low: $5.74
High: $5.88

50 Day Range

MA: $5.43
Low: $4.84
High: $6.08

52 Week Range

Now: $5.76
Low: $4.68
High: $12.96

Volume

10,352 shs

Average Volume

19,624 shs

Market Capitalization

$2.21 billion

P/E Ratio

17.45

Dividend Yield

2.58%

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Elekta AB (publ)?

The following equities research analysts have issued stock ratings on Elekta AB (publ) in the last twelve months: Danske, Jefferies Financial Group Inc., JPMorgan Chase & Co., and Morgan Stanley.
View the latest analyst ratings for EKTAY.

What is the current price target for Elekta AB (publ)?

1 Wall Street analysts have set twelve-month price targets for Elekta AB (publ) in the last year. Their average twelve-month price target is $69.00, suggesting a possible upside of 1,097.9%. JPMorgan Chase & Co. has the highest price target set, predicting EKTAY will reach $69.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $69.00 for Elekta AB (publ) in the next year.
View the latest price targets for EKTAY.

What is the current consensus analyst rating for Elekta AB (publ)?

Elekta AB (publ) currently has 3 sell ratings and 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe EKTAY will underperform the market and that investors should sell shares of Elekta AB (publ).
View the latest ratings for EKTAY.

What other companies compete with Elekta AB (publ)?

Other companies that are similar to Elekta AB (publ) include Veracyte, RadNet, Fulgent Genetics, Invitae and Viridian Therapeutics. Learn More about companies similar to Elekta AB (publ).

How do I contact Elekta AB (publ)'s investor relations team?

Elekta AB (publ)'s physical mailing address is P.O. Box 7593, Stockholm V7, SE-103 93. The company's listed phone number is (685) 872-5400 and its investor relations email address is [email protected] The official website for Elekta AB (publ) is www.elekta.com. Learn More about contacing Elekta AB (publ) investor relations.